{"transactions":[{"id":1840803,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-30T20:34:47.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":19787969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on July 22, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":19787969,"derivative":{"exercise_price":0.3,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":19787969},"source":{"system":"sec-edgar","filing":"0001209191-23-040338","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919123040338/doc4.xml","form_type":"4"}},{"id":1992291,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-24T23:20:36.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":640000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":640000,"derivative":{"exercise_price":0.44,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":640000},"source":{"system":"sec-edgar","filing":"0001209191-23-012875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919123012875/doc4.xml","form_type":"4"}},{"id":2173655,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-08-25T23:34:22.000Z","date":"2022-08-23","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.  Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested."}],"balance_after":130000,"derivative":{"exercise_price":0.68,"expiration_date":"2032-08-22","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001209191-22-047648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919122047648/doc4.xml","form_type":"4"}},{"id":2332675,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-15T22:30:51.000Z","date":"2022-03-11","kind":"purchase","acquired":true,"shares":75000,"price":2.08,"value":156000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":165372,"source":{"system":"sec-edgar","filing":"0001209191-22-018941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919122018941/doc4.xml","form_type":"4"}},{"id":2381463,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T21:50:32.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":170000,"derivative":{"exercise_price":3.17,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001209191-22-011704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919122011704/doc4.xml","form_type":"4"}},{"id":2474978,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-14T01:37:40.000Z","date":"2021-12-09","kind":"purchase","acquired":true,"shares":50000,"price":3.72,"value":186000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":90372,"source":{"system":"sec-edgar","filing":"0001209191-21-069349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919121069349/doc4.xml","form_type":"4"}},{"id":2597190,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T21:21:54.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":7200,"price":6.7222,"value":48399.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.77 per share, inclusive."}],"balance_after":40372,"source":{"system":"sec-edgar","filing":"0001209191-21-052272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919121052272/doc4.xml","form_type":"4"}},{"id":2597189,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T21:21:54.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":23392,"price":6.4973,"value":151984.8416,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.6 per share, inclusive."}],"balance_after":33172,"source":{"system":"sec-edgar","filing":"0001209191-21-052272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919121052272/doc4.xml","form_type":"4"}},{"id":2597188,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T21:21:54.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":9780,"price":6.3676,"value":62275.128,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.13 to $6.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."}],"balance_after":9780,"source":{"system":"sec-edgar","filing":"0001209191-21-052272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919121052272/doc4.xml","form_type":"4"}},{"id":2637749,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":111731,"kind":"person","name":"Alspaugh Jonathan","position":1,"cik":"0001868112","reported_name":"Alspaugh Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-07-08T21:12:17.000Z","date":"2021-07-06","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 1/4th of the total shares on July 6, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on July 6, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":160000,"derivative":{"exercise_price":7.03,"expiration_date":"2031-07-05","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-21-046007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000120919121046007/doc4.xml","form_type":"4"}}]}